Search

Your search keyword '"Zengerling, Friedemann"' showing total 438 results

Search Constraints

Start Over You searched for: Author "Zengerling, Friedemann" Remove constraint Author: "Zengerling, Friedemann"
438 results on '"Zengerling, Friedemann"'

Search Results

4. First-Line Immune Combination Therapies for Nonclear Cell Versus Clear Cell Metastatic Renal Cell Carcinoma: Real-World Multicenter Data From Germany

6. Xpert bladder cancer monitor to predict the need for a second TURB (MoniTURB trial)

19. Therapy of clinical stage IIA and IIB seminoma: a systematic review

20. Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial

21. Enfortumab Vedotin in Metastatic Urothelial Carcinoma: Survival and Safety in a European Multicenter Real-world Patient Cohort

24. Tailored immunotherapy approach with nivolumab with or without ipilimumab in patients with advanced transitional cell carcinoma after platinum-based chemotherapy (TITAN-TCC): a multicentre, single-arm, phase 2 trial

25. INSIGHT-005: A new stratum of the explorative, open-labeled, phase I INSIGHT study to evaluate the feasibility and safety, as well as preliminary efficacy, of subcutaneous injections with IMP321 (eftilagimod alpha) in combination with PD-L1 inhibitor (avelumab) for metastatic or unresectable locally advanced urothelial carcinoma (UC)—IKF-s614.

26. Final Results from SAUL, a Single-arm International Study of Atezolizumab in Unselected Patients with Pretreated Locally Advanced/Metastatic Urinary Tract Carcinoma

27. Improving detection of carcinoma in situ in bladder cancer: urinary cytology vs the Xpert® BC Monitor

29. Single-dose carboplatin followed by involved-node radiotherapy for stage IIA and stage IIB seminoma (SAKK 01/10): a single-arm, multicentre, phase 2 trial

30. Predictors for the utilization of social service counseling by prostate cancer patients

35. NECTIN4 Amplification Is Frequent in Solid Tumors and Predicts Enfortumab Vedotin Response in Metastatic Urothelial Cancer

36. Adherence to European Association of Urology and National Comprehensive Cancer Network Guidelines Criteria for Inguinal and Pelvic Lymph Node Dissection in Penile Cancer Patients—A Survey Assessment in German-speaking Countries on Behalf of the European Prospective Penile Cancer Study Group

38. Adressen

39. Nivolumab + Ipilimumab as Immunotherapeutic Boost in Metastatic Urothelial Carcinoma: A Nonrandomized Clinical Trial.

40. Supplementary Table S4 from Detection of Recurrence through microRNA-371a-3p Serum Levels in a Follow-up of Stage I Testicular Germ Cell Tumors in the DRKS-00019223 Study

41. Supplementary Figure S1 from Detection of Recurrence through microRNA-371a-3p Serum Levels in a Follow-up of Stage I Testicular Germ Cell Tumors in the DRKS-00019223 Study

42. Data from Detection of Recurrence through microRNA-371a-3p Serum Levels in a Follow-up of Stage I Testicular Germ Cell Tumors in the DRKS-00019223 Study

43. Psychometric validation of the German version of the EPIC-26 questionnaire for patients with localized and locally advanced prostate cancer

45. Detection of recurrence through microRNA-371a-3p serum levels in a follow-up of stage I testicular germ cell tumors in the DRKS-00019223 study

46. Occurrence of NECTIN4 amplification in solid tumors and enfortumab vedotin response in metastatic urothelial cancer.

47. CRP kinetics to predict long-term efficacy of first-line immune-checkpoint inhibition combination therapies in metastatic renal cell carcinoma: An updated multicenter real-world experience applying different CRP kinetics definitions.

Catalog

Books, media, physical & digital resources